Withdrawal versus continuation of guideline-directed medical therapy in heart failure with improved ejection fraction: a systematic review and meta-analysis
References
- HEIDENREICH PA, BOZKURT B, AGUILAR D, ALLEN LA, BYUN JJ, COLVIN MM, et al. AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17).
- BOZKURT B, COATS AJS, TSUTSUI H, ABDELHAMID CM, ADAMOPOULOS S, ALBERT N, et al. Universal definition and classification of heart failure. Eur J Heart Fail. 2021;23(3):352–80
- BASURAY A, FRENCH B, KY B, VOROVICH E, OLT C, SWEITZER NK, et al. Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation. 2014;129(23):2380–2387.
- MANN DL, BARGER PM, BURKHOFF D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol. 2012;60(24):2465–2472.
- HALLIDAY BP, WASSALL R, LOTA AS, KHALIQUE Z, GREGSON J, NEWSOME S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019;393(10166):61–73.
- BAKHSH A, THANASSOULIS G, ENGERT JC, ELSTEIN E, HUYNH T, GIANNETTI N. Withdrawal of beta-blockers and ACE inhibitors after left ventricular systolic function recovery in dilated cardiomyopathy. Eur Heart J. 2020;41(Suppl 2):ehaa946.081.
- SEGAN L, KISTLER PM, NANAYAKKARA S, TAYLOR A, HARE J, COSTELLO B, et al. Withdrawal of heart failure therapy after atrial fibrillation rhythm control with ejection fraction normalization: the WITHDRAW-AF trial. Eur Heart J. 2026;47(2):250–262.
- CHEN QF, LU Y, KATSOURAS CS, PENG Y, SUN J, LI M, et al. Characteristics, outcomes, and the necessity of continued guideline-directed medical therapy in patients with heart failure with improved ejection fraction. Ann Med. 2025;57(1):2442535.
- VADUGANATHAN M, CLAGGETT BL, JHUND PS, CUNNINGHAM JW, FERREIRA JP, ZANNAD F, et al. Continuation versus withdrawal of guideline-directed medical therapy in heart failure with improved ejection fraction. Circulation. 2024.
- CHEN Y, QIU Z, JIANG J, SU X, HUANG F, TANG J, et al. Outcomes of spironolactone withdrawal in dilated cardiomyopathy with improved ejection fraction. Front Cardiovasc Med. 2021;8:725399.
- LEE SH, RHEE TM, SHIN D, HONG D, CHOI KH, KIM HK, et al. Prognosis after discontinuing the renin-angiotensin-aldosterone system inhibitor for heart failure with restored ejection fraction after acute myocardial infarction. Sci Rep. 2023;13:3539.
- BASILE C, LINDBERG F, BENSON L, GUIDETTI F, DAHLSTRÖM U, PIEPOLI MF, et al. Withdrawal of guideline-directed medical therapy in patients with heart failure and improved ejection fraction. Circulation. 2025;151(13):931–945.
Language: English
Submitted on: Mar 8, 2026
Published on: Jul 22, 2026
Published by: N.G. Lupu Internal Medicine Foundation
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2026 Juan Camilo Hernández Jaramillo, Juan Esteban Suárez Muñoz, María Cristina Oviedo Arroyo, María José Díaz Gutiérrez, Gloria Ibis Tirado Romero, published by N.G. Lupu Internal Medicine Foundation
This work is licensed under the Creative Commons Attribution 4.0 License.